Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x100px
Document › Details

Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen.

Organisations Organisation Immatics N.V. (Nasdaq: IMTX)
  Group Immatics (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product IMA203 TCR-T candidate targeting PRAME (ACTengine)
  Product 2 phase 1 study
Persons Person Britten, Cedrik (Immatics 202006– CMO before GSK VP + Head of Oncology Cell Therapy Research Unit + BioNTech)
  Person 2 Silverstein, Jordan (Immatics 202003 Head of Corporate Strategy before InflaRx + Advanced Accelerator Applications)
     


   
Record changed: 2024-10-10

Advertisement

Picture biomindz TRON LSG Mainz Translation Cancer Immunotherapy 650x200px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x300px




» top